Therapeutics Articles
The U.S. market for IVIG continues to grow well over 5 percent annually. What is driving the market demand?
Gene therapy is the one remaining therapeutic option for treating severe combined immunodeficiency by correcting it at its most fundamental genetic level.
Advancements in stem cell therapy may soon eliminate surgeries and cure disease, but first, the debate between two different schools of thought concerning how best to proceed needs to be resolved.
New extended half-life products represent a powerful new tool for improving the care and quality of life for persons with hemophilia.
As it has since the first commercially produced factor VIII concentrate transformed the lives of U.S. hemophilia A patients, innovation is still the life-blood of this industry.
